Novavax stock spikes 20% after company snags $350 million from Canada for unused Covid shots

It’s unclear how many doses of Novavax’s jab – its only commercially available product after 35 years – went unused. Under the amended agreement, Novavax will also provide Canada with fewer doses of its vaccine on a revised delivery schedule. 

However, Canada can terminate the contract if Novavax fails to receive regulatory approval for vaccine production at the Canadian government’s biomanufacturing facility by Dec. 31, 2024, according to the agreement.

The announcement is another sign of hope for investors after the cash-strapped company raised doubts about its ability to stay in business earlier this year. 

In May, Novavax adopted a more positive outlook and announced a sweeping cost-cutting plan alongside its first-quarter earnings report. The company said it expects 2023 revenue of between $1.4 billion and $1.6 billion.

Novavax’s stock price jumped around 30% on that news, but Wall Street hasn’t entirely bought into the recovery plan: The company’s stock price is still down roughly 15% since the start of the year after shedding more than 90% of its value in 2022.

Novavax still faces a number of challenges ahead, including competing with Pfizer and Moderna in the commercial Covid vaccine market and a pending $700 million arbitration over a canceled vaccine purchase agreement.